ADPGK

Across TCGA pan-cancer cohorts, ADPGK Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADPGK data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ADPGK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADPGK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, COAD, and UCEC are the cancer types where ADPGK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
COAD	OS	Median	II,III,IV	0.118	0.646	.023	9	view →
UCEC	DFS	Median	All	1.000	0.629	.025	8	view →
SARC	OS	Median	All	0.224	0.839	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADPGK–MESO (OS)

Open the MESO breakdown →